Dynavax Technologies Corporation (DVAX)
| Market Cap | 978.53M |
| Revenue (ttm) | 46.55M |
| Net Income (ttm) | -75.24M |
| Shares Out | 100.75M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $8.49 |
| Previous Close | $8.64 |
| Change ($) | -0.15 |
| Change (%) | -1.74% |
| Day's Open | 8.60 |
| Day's Range | 8.31 - 8.83 |
| Day's Volume | 3,056,306 |
| 52-Week Range | 1.80 - 12.44 |
EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announc...
EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that in connection with the commencement of Ms. MacDonald's employment with the...
The biotech's better-than-expected Q4 update pointed to even better days ahead.
The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.
EMERYVILLE, Calif., Feb. 25, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today r...
Is (DVAX) Outperforming Other Medical Stocks This Year?
EMERYVILLE, Calif., Feb. 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today a...
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies (DVAX) closed the most recent trading day at $9.82, moving +0.41% from the previous trading session.
EMERYVILLE, Calif., Feb. 16, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announc...
Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
EMERYVILLE, Calif., Feb. 8, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announce...
EMERYVILLE, Calif., Feb. 3, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 7,500...
Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussi...
Dynavax Technologies Corporation (NASDAQ: DVAX) shares are advancing solidly after the company and Clover Biopharma issued an update on their joint coronavirus vaccine program. What Happened: ...
EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today an...
OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel v...
Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum in the first half of 2021 with ...
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causin...
TAIPEI, TAIWAN and EMERYVILLE, Calif., Jan. 25, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO) a biopharmaceutical company focusing on the development and pr...
EMERYVILLE, Calif., Jan. 20, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announc...
The company reported positive clinical results for its hepatitis B vaccine.
EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announce...
PUNE, India and EMERYVILLE, Calif., Dec. 23, 2020 /PRNewswire/ -- Further strengthening its fight against COVID-19, Serum Institute of India (SIIPL), the world's largest vaccine manufacturer b...
EMERYVILLE, Calif., Dec. 10, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today a...
CHENGDU, China.--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the...
EMERYVILLE, Calif., Nov. 17, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today a...
HYDERABAD, India and HOUSTON and EMERYVILLE, Calif., Nov. 16, 2020 /PRNewswire/ -- Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies Corpo...
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25.00% and 21.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q3 2020 Results - Earnings Call Transcript
Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Dynavax Technologies (DVAX) closed at $3.87, marking a -1.53% move from the previous day.
Dynavax Technologies (DVAX) closed the most recent trading day at $4.17, moving +0.72% from the previous trading session.
Investors ran out of patience with this COVID-19 stock last month.
CHENGDU, China--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, ...
EMERYVILLE, Calif., Sept. 24, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today ...
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.
Dynavax will provide CpG 1018 to produce up to 190 million doses over a five year period to support Valneva’s contract with the U.K. government
Even these top contenders had a rough end to the summer.
Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.
Short-sellers are betting against these stocks big time. But that could set up big opportunities for investors if these biotechs have positive news on the way.
EMERYVILLE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,...
EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,...
This biotech has a vaccine for treating hepatitis B and is now tackling COVID-19. But it's still valued at less than $1 billion.
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of ... [Read more...]
| Industry Biotechnology | IPO Date Feb 19, 2004 |
| CEO Ryan Spencer | Employees 245 |
| Stock Exchange NASDAQ | Ticker Symbol DVAX |
Financial Performance
In 2020, DVAX's revenue was $46.55 million, an increase of 32.18% compared to the previous year's $35.22 million. Losses were -$75.24 million, -50.69% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for DVAX stock is "Strong Buy." The 12-month stock price forecast is 18.00, which is an increase of 112.01% from the latest price.